PB 01

Drug Profile

PB 01

Alternative Names: PB01

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Hudson Institute of Medical Research
  • Developer Paranta Biosciences
  • Class Carrier proteins; Glycoproteins; Recombinant proteins
  • Mechanism of Action Activin receptor antagonists; Cell differentiation modulators; Follicle stimulating hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis
  • Preclinical Cancer

Most Recent Events

  • 23 Nov 2016 Paranta completes a phase I trial in Healthy volunteers in Australia (ACTRN12616000496415)
  • 30 Sep 2015 Preclinical trials in Cancer in Australia (IV)
  • 22 Sep 2015 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Australia (Inhalation) (ACTRN12615000984594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top